SCHEMBL14313302

SCHEMBL14313302

Nc1ncnn2c(C=CCCN3CCCC3)cc(-c3cccc(OCc4ccccc4)c3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 19/20 0.46
▸ INSR P06213 8/20 0.46
▸ LYN P07948 7/20 0.46
▸ FGFR1 P11362 6/20 0.46
▸ FLT4 P35916 6/20 0.46
▸ FLT3 P36888 6/20 0.46
▸ ROCK2 O75116 6/20 0.46
▸ LCK P06239 5/20 0.46
▸ KDR P35968 5/20 0.46
▸ STK3 Q13188 5/20 0.46
▸ ROCK1 Q13464 5/20 0.46
▸ PRKD2 Q9BZL6 5/20 0.46
▸ ERBB4 Q15303 4/20 0.46
▸ RPS6KB1 P23443 4/20 0.46
▸ AURKB Q96GD4 4/20 0.46
▸ SRC P12931 4/20 0.46
▸ KIT P10721 4/20 0.46
▸ FLT1 P17948 4/20 0.46
▸ CHEK2 O96017 4/20 0.46
▸ CSF1R P07333 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14313301 1.00 IGF1R (0.46) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14531757 0.82 IGF1R (0.50) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14312916 0.81 IGF1R (0.49) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14312895 0.81 IGF1R (0.49) IGF1RINSRLYNFGFR1FLT4
SCHEMBL5080937 0.81 IGF1R (0.49) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14312887 0.81 IGF1R (0.49) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14313201 0.80 IGF1R (0.49) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14312818 0.78 ACVRL1 (0.49) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14313261 0.77 ACVRL1 (0.45) IGF1RINSRLYNFGFR1FLT4
SCHEMBL14312903 0.77 ACVRL1 (0.46) IGF1RINSRLYNFGFR1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1945222-B1 PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES Bayer Pharma AG (DE) 2012-12-26 — — EP disclosed
Send feedback